Navigation Links
NeurogesX to Present at Lazard Capital Markets Healthcare Conference
Date:11/26/2007

SAN MATEO, Calif., Nov. 26 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, announced today that it is scheduled to present on Wednesday, November 28, 2007 at the Lazard Capital Markets Healthcare Conference in New York City. Anthony DiTonno, President and Chief Executive Officer, will be presenting and Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions during the break out session.

Event: Lazard Capital Markets Healthcare Conference

Date: Wednesday, November 28, 2007

Time: 3:00 p.m. ET

Place: New York Palace Hotel, New York

An audio Web cast of the Company's presentations will be available by going to the investor relations section of NeurogesX' Web site at http://www.neurogesx.com. A replay of the presentation will be available for 15 days.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX- 4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
7. Avicena Group to Present at Noble Financial Conference
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CEL-SCI to Present at the Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has ... now comes with a second treatment cup to help prevent ... new cup is thinner on the edges for a softer ... thin and uneven surfaces on the face, neck and décolleté. ... treatment on areas such as the cheeks and neck, or ...
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
(Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, ... report to their offering. ... photonic integration traces its roots in the latter ... photonic integration went unexplored and unfulfilled for several ...
(Date:7/10/2014)... help in the fight against terrorism with the creation ... explosives with the use of light and special glass ... Actuators B: Chemical , the researchers describe a novel ... as low as 6.3 ppm (parts per million). It ... , "Traditionally explosives detection has involved looking for metals ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2
... Danaher Corporation (NYSE: DHR ) announced today ... approximately 97% of the currently issued shares of Genetix Group ... dated December 18, 2009. , Danaher intends to acquire any ... acquisition provisions of the applicable UK companies legislation. , ...
... , TSX Exchange Symbol: RVX , Also ... SAN FRANCISCO, CA and CALGARY, Jan. 11 /PRNewswire-FirstCall/ - ... that Donald J. McCaffrey will be presenting at the ... at the Marines, Memorial Club and Hotel in San ...
... , BOSTON, Jan. 11 PAREXEL International ... expectations for the second quarter of Fiscal Year 2010 ended ... ending June 30, 2010. The Company,s updated financial guidance ... business wins and cancellations, revised expectations for the amount and ...
Cached Biology Technology:Danaher Completes Offer for Genetix Group plc 2Resverlogix Presenting at Biotech Showcase 2PAREXEL Issues Updated Financial And Operational Information 2PAREXEL Issues Updated Financial And Operational Information 3PAREXEL Issues Updated Financial And Operational Information 4PAREXEL Issues Updated Financial And Operational Information 5
(Date:7/11/2014)... Recent evidence has demonstrated that transplantation of mesenchymal stem ... rat or mouse models of Alzheimer,s disease (AD) and ... cerebral ischemia. Few studies are reported on the therapeutic ... with AD and on the effect on oxidative injury ... Yufang Yan and her team, School of Life Sciences, ...
(Date:7/11/2014)... proteins that let nerve cells send out electrical signals, ... biological tactic that may offer a new way to ... environmentally responsible way. , Their findingthat naturally occurring ... harmless for a closely related onesuggests that insecticides can ... species like bees. A summary of the research, led ...
(Date:7/10/2014)... 2014  Aware, Inc. (NASDAQ: AWRE ), ... announced on June 26, 2014 that its Board of ... per share, or approximately $40 million in total.  The ... and a payment date of July 24, 2014.  The ... set an ex-dividend date for this special cash dividend. ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... only multi drug-resistant forms of the disease but could also ... infection as well. Researchers report their results today at ... which this compound is the lead has a very different ... treat tuberculosis. We have identified no cross resistance with ...
... great debate has raged over whether organic compounds and ... meteorite Allan Hills 84001 were processed by living creatures ... been under intense scrutiny ever since. Scientists at the ... fresh look at how material associated with carbonate globules ...
... concerns that hamper embryonic stem cell research, but they still ... with which adult stem cells differentiate into mature tissue the ... impossible for researchers to multiply them in the laboratory. And ... difficult to use them for treating disease. , Now, ...
Cached Biology News:Experimental TB drug effective against resistant and latent mycobacterium tuberculosis 2Relic of life in that Martian meteorite? A fresh look 2Powerful technique for multiplying adult stem cells may aid therapies 2Powerful technique for multiplying adult stem cells may aid therapies 3
One-step, colorimetric, linear detection range 0.7 mg/dL to 300 mg/dL. Procedure: 10 min....
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Recombinant Mouse LIGHT/TNFSF14...
Request Info...
Biology Products: